Separation and Study of the Range of Plasminogen Isoforms in Patients with Prostate Cancer

---

E. F. Shin^1*, D. I. Vodolazhsky¹, A. Yu. Golikov¹, T. N. Belova¹, N. V. Boyko¹, D. V. Zimakov¹, E. N. Cherkasova¹, M. I. Kogan², M. B. Chibichian², S. A. Moshkovskii³, V. A. Tarasov¹, and D. G. Matishov¹

¹Institute of Arid Zones, Southern Scientific Center of the Russian Academy of Sciences, pr. Chekhova 41, 344006 Rostov-on-Don, Russia; fax: (863) 266-5677; E-mail: johnnyeugenie@gmail.com

²Rostov State Medical University, Pereulok Nakhichevanskii 29, 344022 Rostov-on-Don, Russia

³Orekhovich Institute of Biomedical Chemistry, Russian Academy of Medical Sciences, ul. Pogodinskaya 10, 119121 Moscow, Russia

^* To whom correspondence should be addressed.

Received April 12, 2012; Revision received May 4, 2012

---

Using affinity chromatography, two-dimensional electrophoresis, and MALDI-TOF mass spectrometry, plasminogen isoforms were separated and identified in blood plasma. Healthy donors and patients with prostate cancer in various stages of development were included in the studied sample. With the development of prostate cancer, four additional specific plasminogen isoforms are registered in blood plasma; they are characterized by lower molecular weights and higher pI values compared to isoforms found in the control group.

---

KEY WORDS: plasminogen isoforms, two-dimensional electrophoresis, MALDI-TOF-MS, prostate cancer

DOI: 10.1134/S0006297912090143

---